Announced
Fosun Pharma to acquire Henlius for HKD5.4bn.
Synopsis
Fosun Pharma, a Chinese listed pharmaceutical company, offered to acquire Henlius, a global biopharmaceutical company, for HKD5.4bn. Henlius, as a core innovative asset of Fosun Pharma, will benefit from sustainable growth and enhance Fosun Pharma’s strategic goals in the innovative biopharmaceutical sectors upon the completion of the transaction.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.